Treating Localized Prostate Cancer Boosts Survival

    body {
    background: #FFF;

    Survival rates for men with localized prostate cancer are better with either
    surgery or radioactive seed implantation, a treatment called brachytherapy,
    compared with no “definitive” treatment, investigators at the University of Utah
    in Salt Lake City report. This is true even among older men.

    Based on the
    research, reported in the journal Cancer, men undergoing surgery or
    brachytherapy are much less likely to die of prostate cancer or any cause
    compared with men undergoing no definitive therapy.

    “This study is the
    first to demonstrate an apparent overall survival advantage for brachytherapy
    compared with no definitive treatment, and validates prior reports that document
    a survival advantage for surgery,” Dr. Jonathan D. Tward and associates

    Nonetheless, only a
    small number of men with localized prostate cancer will die of the disease
    within 10 years, the investigators note, and both surgery and brachytherapy are
    invasive procedures with possible lifetime side-effects.

    “Factors other than
    survival, such as risks, side effect profiles, and quality of life weigh heavily
    on men deciding to undergo treatment for this disease, which is unlikely to
    claim their life,” the authors comment. For those who opt for definitive
    treatment, “both younger and older men should be counseled that either surgery
    or brachytherapy is appropriate.”

    Using the National
    Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database of
    60,269 men diagnosed with localized prostate cancer between 1998 and 2002, Tward
    and colleagues assessed the rate of death due to prostate cancer or any cause
    after a median of 46 months.

    Outcomes of
    brachytherapy, removal of the prostate (prostatectomy) or no definitive
    treatment were assessed for men less than 60 years of age at diagnosis and those
    aged 60 years and older.

    cancer-specific mortality rates at 10 years for the younger age group were 1.3
    percent with surgery, 0.5 percent with brachytherapy and 3.7 percent with no
    definitive therapy.

    For older men, corresponding mortality rates were 3.8 percent with
    surgery, 5.3 percent with brachytherapy and 8.4 percent with no definitive

    • advertisement
    • advertisement

    Get every new post delivered to your Inbox.

    Join 2,465 other followers